What are the updates from the NCRI AML18 and AML19 clinical trials?

During the 4th National Cancer Research Institute (NCRI) AML Academy Meeting, the AML Hub was pleased to speak to Nigel Russell, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What are the updates from the NCRI AML18 and AML19 clinical trials?

Russell begins by discussing results from the AML19 clinical trial, where younger adult patients with acute myeloid leukemia or high-risk myelodysplastic syndromes were treated with either a single or fractionated dose of gemtuzumab ozogamicin paired with either daunorubicin-cytarabine or FLAG-Ida chemotherapy regimens followed by consolidation treatment with high-dose cytarabine. Russell considers survival and minimal residue disease negativity rates, outcomes in mutational subgroups, and the use of CPX-351 in specific patient populations.

Russell then goes on to highlight findings from the AML18 clinical trial, in which elderly patients without adverse-risk cytogenetics disease were treated with daunorubicin-cytarabine chemotherapy with or without single or fractionated dose gemtuzumab ozogamicin. Finally, Russell discusses the differences in survival rates and minimal residue disease negativity in those who received a stem cell transplant and the implications of these results on the choice of induction chemotherapy in this patient population.